The following webcasts are scheduled. Participation is free, so please register to participate.
Please be aware that Webinars are hosted through GoToWebinar. If you are not already set up to view webinars through this service, please allow 5 minutes before the start of the webinar to establish access.
Date: October 23rd, 2014 16: 00-16: 40 GMT (London time)
Molecular characterisation of circulating tumor cells (CTCs) and/or cell free tumor DNA (cfDNA) offers the opportunity for personalized targeted therapy and real-time monitoring of treatment efficacy. The development of novel platforms to assess the presence of cfDNA is challenging due to the difficulty in obtaining a sustainable source of patient-relevant material. This study presents the design and validation of our HDx Multiplex Low Copy Number Reference Standards and their performance in assays optimised for cfDNA detection. The results indicate the successful generation of precisely defined reference material including one EGFR standard containing 25 copies of each G719S, ΔE746-A750, T790M, L858R and L861Q mutation in a total EGFR background of 50000. This equates to 1 mutant cell in 1000 wild type cells and an appropriate level to analyse the performance of the cfDNA assays. We will discuss the clinical application, development and validation of reference materials for cell free DNA assays
Date: November 12th, 2014 16: 00-16: 30 GMT (London time)
Personalised medicine has changed the landscape of cancer drug discovery. Tools such as panels of isogenic cell lines, RNAi screening platforms and assays that mimic the tumour environment all contribute to greater understanding of disease and more accurate prediction of patient responses to drugs and drug combinations. At this free webinar, we will describe how Horizon Discovery Services can help you to answer key questions, including identification of on-target drug activity, identification of responsive or resistant patient populations, compound profiling and detailed mechanism of action studies, and effects of the tumour microenvironment on tumour growth and drug response (3D assay systems).
Date: December 9th, 2014 16: 00-16: 30 GMT (London time)
Horizon is a world-leader in genome-editing, and in this free webinar we discuss our approach to RNAi screening using siRNA and CRISPR-Cas9 sgRNA technologies. Topics will include introduction to RNAi technologies, use of X-MAN™ isogenic cell lines in RNAi screening approaches, comparison of siRNA and sgRNA screening approaches, possibilities and challenges of genome-wide CRISPR-Cas9 knockout (GeCKO) screening, and examples of synthetic lethal screenings using siRNA and CRISPR-Cas9 sgRNA technologies for target identification and patient stratification.
Paragraph explaining benefits of Biocair×